Author:
Wu Yuanfeng,Beland Frederick A.,Chen Si,Liu Fang,Guo Lei,Fang Jia-Long
Funder
U.S. Department of Energy
FDA
Subject
Pharmacology,Biochemistry
Reference65 articles.
1. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan;Friedman;J. Crit. Care,2013
2. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia;Schrier;N. Engl. J. Med.,2006
3. Tolvaptan in patients with autosomal dominant polycystic kidney disease;Torres;N. Engl. J. Med.,2012
4. Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects;Shoaf;Eur. J. Clin. Pharmacol.,2012
5. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects;Shoaf;Br. J. Clin. Pharmacol.,2012
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献